SSA
ABBV icon

Schonfeld Strategic Advisors’s AbbVie ABBV Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,300
Closed -$3.83M – 1982
2025
Q1 		$3.83M Buy
+18,300
New +$3.56M 0.02% 633

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Schonfeld Strategic Advisors's ABBV Position: Q2 2026 in Review

Schonfeld Strategic Advisors increased its AbbVie (ABBV) stake by 97% in Q2 2026, buying an estimated $11M and bringing the position to 104,287 shares worth $26.2M. The position accounts for 0.09% of the portfolio, ranked #187.

Schonfeld Strategic Advisors first reported a position in ABBV in Q3 2016 and has held it in 35 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Schonfeld Strategic Advisors held 104,287 shares of AbbVie worth $26.2M as of Q2 2026.
  • Schonfeld Strategic Advisors bought 51,227 AbbVie shares in Q2 2026, an estimated $11M.
  • AbbVie made up 0.09% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #187 holding.
  • Schonfeld Strategic Advisors first reported a position in AbbVie in Q3 2016 and has held it in 35 quarters since.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.